OVERSEA CHINESE BANKING Corp Ltd Increases Position in Moderna, Inc. $MRNA

OVERSEA CHINESE BANKING Corp Ltd increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,241 shares of the company’s stock after purchasing an additional 8,469 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Moderna were worth $1,356,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MRNA. S Bank Fund Management Ltd purchased a new position in shares of Moderna in the 1st quarter valued at about $25,000. TD Private Client Wealth LLC increased its holdings in shares of Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of Moderna in the 1st quarter valued at about $28,000. Whittier Trust Co. purchased a new position in shares of Moderna in the 2nd quarter valued at about $28,000. Finally, CX Institutional grew its stake in Moderna by 1,129.8% in the 2nd quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after acquiring an additional 949 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research note on Thursday, October 23rd. UBS Group lowered their price objective on shares of Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday. Leerink Partners lowered their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research note on Friday, August 22nd. Citigroup lowered their price objective on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. Finally, Morgan Stanley increased their price objective on shares of Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $36.86.

Moderna Price Performance

Moderna stock opened at $26.66 on Tuesday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $57.69. The stock has a market capitalization of $10.41 billion, a P/E ratio of -3.54 and a beta of 2.01. The firm’s 50-day moving average is $25.91 and its two-hundred day moving average is $27.15.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. During the same period last year, the company earned ($3.33) EPS. The firm’s revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.